DOI: 10.1126/scitranslmed.adh9902 2023
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc
1 Stéphanie Braillard, Martine Keenan, Karen J. Breese, Jacob Heppell, Michael Abbott, Rafiqul Islam, David M. Shackleford, Kasiram Katneni, Elly Crighton, Gong Chen, Rahul Patil, Given Lee, Karen L. White, Sandra Carvalho, Richard J. Wall, Giulia Chemi, Fabio Zuccotto, Silvia González, Maria Marco, Julianna Deakyne, David Standing, Gino Brunori, Jonathan J. Lyon, Pablo Castañeda-Casado, Isabel Camino, Maria S. Martinez Martinez, Bilal Zulfiqar, Vicky M. Avery, Pim-Bart Feijens, Natascha Van Pelt, An Matheeussen, Sarah Hendrickx, Louis Maes, Guy Caljon, Vanessa Yardley, Susan Wyllie, Susan A. Charman, Eric Chatelain